Monday, 20 January 2020

Global Coronary Stents Market 2019 Size, Status and Forecast to 2023

Global Coronary Stents Market Research Report: by Products (Drug Eluting Stents, Bare Metal Stents, and Bioresorbable Vascular Scaffolds), By End-Users (Hospitals and clinics, ambulatory surgical center, specialty center, and others) - Forecast Till 2023
Coronary stents are used in the process of angioplasty to make the cross-section of the blood vessel wider. Stents hold the walls of the vessel and thus do not let it sag or shrink, thereby curing the blockages in the vessel. Coronary stents have substantially changed the practice of interventional cardiology by reducing early complications such as abrupt vessel closure and improving late clinical outcome (restenosis). This results in patient and physician satisfaction. Thus, this factor contributes heavily to the growth of this market.
Global Coronary Stents Market is expected to grow significantly over the forecast period. The market held a market value of USD 9,382.63 Million in 2017 and is projected to grow at a CAGR of 7.81% over the forecast period.
Moreover, the wide acceptance of prosthesis in coronary artery treatment procedures also fuels the market growth. Key companies are also engaged in new product launches related to coronary stents owing to the wide acceptance of the product. For instance, in May 2018, Terumo Europe NV announced the launch of Ultimaster Tansei drug eluting stent in Europe.
The market, by coronary stents, is further segmented into drug eluting stents, bare metal stents, and bioresorbable vascular scaffolds. Drug-eluting stents are metal stents that have been coated with a pharmacologic drug known to suppress restenosis, whereas bare metal stents are stents without a covering or a coating. Bioresorbable vascular scaffolds are intended to provide mechanical support and drug delivery similar to drug eluting stents, followed by complete resorption in some years.
Key players:
Abbott, B. Braun Melsungen AG, Biotronik SE & Co. KG, Boston Scientific Corporation, C. R. Bard, Inc., Cook Medical, Elixir Medical Corporation, Medtronic plc, Meril Life Sciences, MicroPort Scientific Corporation, Stentys SA, and Terumo Corporation are some of the key players in the global coronary stents market.
Segmentation:
Global Coronary Stents Market has been segmented into products, and end user.Based on products, the market has been segmented into, Drug Eluting Stents, Bare Metal Stents, and Bioresorbable Vascular Scaffolds. The drug eluting stent segment is expected to account for the largest share in the global coronary stents market in 2017. This large share is majorly attributed to the wider acceptance of the drug eluting stents in the angioplasty procedures, better patient compliance as compared to the bare metal stents. On the other hand, bioresorbable stents are projected to grow at the fastest rate during the forecast period. 
European Coronary Stents Market has been segmented into Western Europe and Eastern Europe where-in Western Europe region is further divided into Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The Coronary Stents Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The coronary stents market in the Middle East & Africa has been segmented into the Middle East and Africa.
On the basis of end users, the market has been segmented into hospitals & clinics, ambulatory surgical centres, specialty centres, and others. The hospitals & clinics segment is expected to account for the largest share in the global coronary stents market in 2017. At the same time, the increasing establishments of the ambulatory surgical centres in the developed and developing countries has led this segment to grow at the fastest rate during the forecast period.Based on the regions, the market for coronary stents is segmented in to, the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The coronary stents market in the Americas region has further been segmented into North America and South America, where-in the North American market is further divided into the US and Canada.
Regional Market Summary 
Geographically, the Americas is anticipated to dominate the global coronary stents market owing to the rising prevalence of the cardiovascular diseases such as cardiac arrhythmia, arterial blockage, and coronary artery disease among others. The development of the better therapeutic approaches and advanced treatment procedures have affected the growth of the American market in a positive way.
According to the data published by the Department of Health, New York in May 2018, percutaneous coronary intervention is one of the two most common procedures performed on patients with coronary artery disease. Besides this, the high medical awareness among American population, high disposable income, presence of the top medical device manufacturers in the region are some of the many factors that drive the growth of the coronary stents market in this region.
Europe is expected to hold the second largest market share in the global coronary stents market. The market growth in this region is majorly attributed to the increasing government support for the device manufacturers. Geographical expansion of companies has led to the wider reach of the medical products and services which has brought a huge change in terms of the acceptance and implementation of the new products as well as procedures. Similarly, Asia-Pacific region has observed a rapid growth in the coronary stents market owing to the development in the medical sector in developing countries like India and China. Moreover, increase in government funding for healthcare, rising R&D expenditure, and growing number of medical device companies in the region has led to its fastest growth during the forecast period. The Middle East and Africa region is anticipated to show minor growth opportunities in the coronary stents market during the forecast period.
Posted by at No comments:

Cold Pain Therapy Market Pegged to Expand Robustly During 2019-2023

Global Cold Pain Therapy Market Research Report, by Product (Gels, Sprays, Patches), Therapy (Icepack Therapy and Chamber Therapy), Application (Musculoskeletal Disorders), End-User (Hospitals and Clinics and Sports person) – Forecast Till 2023
Market Scenario:
Cold pain therapy includes the products used to reduce the pain or inflammation caused by some physical activities such as injury cause during playing or sports activity and sprain in muscle or ligament during gym. Cold therapy includes use of ice or gel packs that are kept in the freezer till needed. This therapy is largely preferred to manage the pain and swelling as it is simple to use, less expensive and gives quick results.
The market of cold pain therapy is expected to grow by increasing the demand for products to reduce the pain without medicines or by reducing the use of medicine consumption. Cold pain therapy is also use for the treatment of tennis elbow, iliotibial band syndrome, plantar fasciitis, carpel tunnel syndrome and patellofemoral pain syndrome and many more. The cold pain therapy market was estimated USD 1.62 billion in 2017 and expected to reach USD 2.12 billion by 2023 at a CAGR of 4.6% during the forecast period. Most of the cold pain therapy are over the counter products available on online pharmacies, retailing or medical shops.  
Segmentation:
The global cold pain therapy market is segmented on the basis of product, application, therapy, and end-user. The cold pain therapy market, by product is segmented into over the counter (OTC) and prescription products. The over the counter products are sub segmented into gels, sprays, patches, cold packs, wraps, pads, and roll-ons use for the treatment of injuries.
The prescription products are sub segmented into motorized and non-motorized devices.
On the basis of application, the cold pain therapy market is segmented into musculoskeletal disorders, post-operative therapy, sports medicine, and post-trauma therapy.
On the basis of therapy, the cold pain therapy market is segmented into icepack therapy, chamber therapy and cryosurgery.
On the basis of end-user, the cold pain therapy market is segmented into hospitals and clinics, sports person, adults, and others.
Key Players:
Some of the key players in the global cold pain therapy market Medline Industries (US), Sanofi (France), Breg (US), DJO Global (US), Pfizer (US), Johnson & Johnson (US), Össur (Iceland), Performance Health (US), Beiersdorf (Germany), Hisamitsu Pharmaceutical (Japan), Rohto Pharmaceutical (US), Romsons Group of Industries (India), and Others.
Regional Analysis:
The Americas is expected to lead the market owing to increase research and development in cold pain therapy, rising demand for the products to reduce the swelling and arthritis pain. According to the Arthritis Foundation it is estimated that 78 million people may be diagnosed with arthritis in 2040. It was also estimated that currently 31 million of Americans are affected with osteoarthritis. The increasing number prevalence of arthritis with in the population may influence the cold pain therapy market.
Europe is anticipated to be the second largest cold pain therapy market during the forecast period. The increasing prevalence of non-traumatic joint disorders such as knee pain, chronic infectious arthritis and crystalline synovitis is rising the demand for cold pain therapy products. The increase in number of surgeries also support the cold pain therapy market.  According to the National Center for Biotechnology Information 2016, publication it was reported that people affected from septic arthritis (SA) ranges between 2 and 10 per 100,000 patients in the US and Western Europe. The increasing geriatric population and increasing cases of arthritis supports the market growth of cold pain therapy market.
Asia-Pacific was expected to be the fastest growing region for the global cold pain therapy market in 2017. The market is expected to witness high growth owing to the increasing geriatric population with arthritis problem and increasing injuries during sports activities, and presence of major players in cold pain therapy market. According to the MoHFW, Government of India, 2017, reported that osteoarthritis is the most common rheumatologic disease affecting the Indian population with the prevalence of 22% to 39%. The increasing prevalence of rheumatologic disease affecting the large number of populations support the cold pain therapy market.
The Middle East and Africa holds the lowest share for cold pain therapy market due to the low per capita income and availability of alternative treatment method. However, the rising demand for pain relieving products may increase the market growth in Middle East and Africa.
Posted by at No comments:
Labels:

Global Superdisintegrants Market 2019 Size, Status and Forecast to 2023

Superdisintegrants Systems Market Research Report by Type (Synthetic Superdisintegrants, Natural Superdisintegrants, and Others), Formulation (Tablets, Capsules), Therapeutic Area (Neurological Diseases, Gastrointestinal Diseases, Oncology, and Others), and Region (America, Europe, APAC, Middle East & Africa)–Global Forecast to 2023
Market Scenario:
The Global Superdisintegrants Market is anticipted to grow at an optimistic CAGR of 7.9% during the forecast period from 2018 to 2023. Disintegrants are substances which are included in drug formula to allow proper disintegration of the capsule or tablet into easily dissolvable particles. This plays a vital function in the fast absorption of medicine which increases its efficacy. Superdisintegrants are slightly modified disintegrants which offer higher efficiency than their traditional counterparts. Observed to have valued at USD 371 Mn in 2017, the global superdisintegrants market is poised to appreciate to reach an estimated value of USD 576.2 Mn by the end of 2023.
The pharmaceutical industry is growing at breakneck speed, becoming a significant part of the healthcare sector. This is primarily due to rising populations of both geriatric patients and pediatric patients. Superdisintegrants are helpful for treatment of patients from this demographic as these tablets are easier to swallow. The growth of these demographics is expected to drive market growth. Moreover, generic drugs are in high demand as patents have begun to run out on several popular drug brands, thus opening up the pharmaceutical industry for increased entry of competition and a rise in the manufacturing of generic drugs, thus driving demand for superdisintegrants.
Emerging markets represent significant opportunity as the healthcare sectors in these regions are growing at a swift pace. Moreover, large patient pools are in these countries are expected to increase demand for fast-acting medication. Market players are likely to establish themselves in the region in an effort to leverage the opportunities available in emerging economies.
Players Covered
Prominent market participants that have been profiled in the report include Asahi Kasei Corporation, DFE Pharma, JRS Pharma, Corel Pharma Chem, Ashland Global Holdings Inc., BASF SE, Roquette Freres, DowDuPont Inc., Merck KGaA, and Avantor Performance Materials, LLC
Market Segmentation
MRFR's analysis of the various segments in the market has been performed on the basis of type, formulation, therapeutic area, and region. Types of superdisintegrants have been segmented into synthetic superdisintegrants, natural disintegrants, and others. Among these, the synthetic superdisintegrants segment has been widely used, making it the most significant market segment. However, the natural superdisintegrants segment is growing at a truly rapid pace due to the growing demand for natural ingredients.
Formulations which include superdisintegrants have been segmented into tablets and capsules. Tablets govern a majority share of the total market, while the capsules segment is expected to grow at the highest CAGR during the review period.
Therapeutic areas where superdisintegrants are used have been segmented into gastrointestinal diseases, neurological diseases, oncology, infectious diseases, inflammatory diseases, hematological diseases, and cardiovascular diseases. Among these segments, the gastrointestinal diseases segment is at the forefront of market growth due to the demand for fast acting medicine for these types of diseases. Meanwhile, the oncology segment is growing rapidly and is expected to display the highest CAGR over the forecast period.
Regional Analysis
Led by the U.S, the Americas have captured the largest share of the global superdisintegrants market. The presence of a developed healthcare sector as well as several important market players that have and continue to influence growth and contribute to the sizeable share that this regional market possesses. The region also has a high demand for drugs for many chronic diseases where superdisintegrants are required due to the prevalence of such diseases.
The Asia Pacific superdisintegrants market is likely to grow at the highest pace due to the concentration of rapidly emerging markets in the region. China, Japan, India, and several other country-level markets have a high demand for drugs for chronic diseases. The APAC regional market has several avenues for growth that are expected to open up in the coming years. The regions rapidly growing healthcare sector and the presence of a number of contract manufacturing organizations for pharmaceuticals is likely to have a positive impact on the market.
Posted by at No comments:
Labels:

Gestational Trophoblastic Disease Market: Global Major Key Players Research – Forecast to 2023

Global Gestational Trophoblastic Disease Research Report: By Type (Hydatidiform Mole, Choriocarcinoma, Placental-Site Trophoblastic Tumor, and Others), by Treatment (Surgery, Suction Dilation and Curettage, and Others), by End User—Forecast Till 2023
Market Scenario:
Gestational trophoblastic disease (GTD) is a cluster of rare tumors that include abnormal growth of cells inside a woman's uterus. It arises from placental trophoblastic tissue and is characterized by β-subunit of human chorionic gonadotrophin (β HCG). The increasing prevalence of risk factors such as smoking, sexually transmitted diseases (STD), history of miscarriages, and high maternal age are expected to fuel the growth of the market during the forecast period. Rise in ectopic pregnancies is also a significant factor which causes GTD. According to the National Center for Biotechnology Information (NCBI), the risk of ectopic pregnancy is 20 times higher in women who smoke. On the other hand, high risks of recurrence and complications that may occur after the therapy and treatment procedure may hinder the growth of the market during the forecast period.
The global gestational trophoblastic disease market is currently dominated by many market players. The key players in the market are involved in new product launches and strategic partnerships to strengthen its market position. For instance, in September 2018, Novartis AG entered into a license and collaboration agreement with Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company which develops therapies for cancer and degenerative diseases in Greater China.
Competitive Landscape:
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals PLC
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Antares Pharma
  • Mylan N.V.
  • Novartis AG
  • BP Pharmaceuticals Laboratories Company
  • Fresenius Kabi AGAccord Healthcare, Inc.
  • Eli Lilly and Company
  • Sanofi
  • Bayer AG
  • Amgen Inc.
  • Merck
Segmentation:
The global gestational trophoblastic disease market has been segmented into type, treatment, and end user.
The market, on the basis of type, has been segmented into a hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumor, epithelioid trophoblastic tumor, and others.
The market, based on the hydatidiform mole, has been further segmented into a complete, partial and invasive mole. The market, based on hydatidiform mole is expected to hold the largest share as it is the most common form of the gestational trophoblastic disease,  whereas choriocarcinoma is projected to be the fastest-growing market as the incidence rate of this form is increasing steadily according to a journal published by National Center for Biotechnology Information.
The market, by treatment, has been segmented into surgery, chemotherapy, suction dilation and curettage (D&C), and radiation therapy.
The market, based on surgery, has been sub-segmented into an abdominal hysterectomy and vaginal hysterectomy.
The market, by end user, has been segmented into hospital and clinics, diagnostic centers, and others.
The market has been segmented regionally into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The gestational trophoblastic disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European gestational trophoblastic disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The gestational trophoblastic disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The gestational trophoblastic disease market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Geographically, the Americas is projected to dominate the global gestational trophoblastic disease market owing to an increased awareness about the disease and favorable reimbursement scenario. Also, the rise in a number of marketing approvals, as well as product approvals in the field of oncology drive the market growth.
Europe is expected to hold the second largest position in the global gestational trophoblastic disease market. The market growth in this region is attributed to the availability of funds for research and an increasing healthcare expenditure.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.
On the other hand, the Middle East and Africa has the least share of the market. This is due to the stringent government regulations and lack of technical expertise in the treatment of the disease.
Posted by at No comments:

Friday, 17 January 2020

Global Nasal Drug Delivery Market Trends, Demand and Forecast to 2023

Global Nasal Drug Delivery Market Research Report: Information by Drug Type (Anesthetics, Antibiotics), Dosage Form (Drops, Sprays), Basis of System (Unit Dose, Multi-Dose), Delivery Technologies (Spray, Nebulizers), Therapeutic Applications (Rhinitis, Asthma) End User (Home Care Settings) and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2025
Market Scenario
The global nasal drug delivery market is expected to grow significantly over the forecast period. The global market was valued at approximately USD 52,998.5 million in 2018 and is projected to grow with 6.6% CAGR over the forecast period.
Nasal drug delivery is administration of drug through the nasal track to treat various respiratory problems such as paranasal sinuses, nasal infection, and other nasal problems. It is an effective delivery method for medicines that are active in low doses.
Factors such as the painless drug administration, development of new nasal drug delivery technology market, and the increasing number of patient population with respiratory problem are expected to drive the market growth. Moreover, nasal drug delivery devices are easily accessible and suitable for self-medication it has received positive response from patient population, clinicians, and pharmaceutical scientists. 
However, factors such as low bioavailability, nasal irritation, and irreversible damage of cilia of cell is expected to hamper the market growth.
Segmentation
The global nasal drug delivery market has been segmented into drug type, dosage form, basis of system, delivery technologies, therapeutic applications, end users, and region.
Based on drug type, the global market has been segmented into anesthetics, antibiotics, pain relief drugs, calcium supplements, vasoconstrictors, antihistamines, and others.
Based on dosage form, the global market has been segmented into drops, sprays, powder, gels, and ointments.
Based on the basis of system, the global nasal drug delivery market has been segmented into unit dose, multi-dose, and metered dose.
Based on delivery technologies, the global market has been segmented into spray, nebulizers, inhalers, and others.
Based on therapeutic applications, the global market has been segmented into rhinitis, asthma, nasal congestion, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others.
The global market, by end user, has been divided into home care settings and hospitals & clinics.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nasal drug delivery market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European nasal drug delivery market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Asia-Pacific nasal drug delivery market has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The nasal drug delivery market in the Middle East & Africa has been segmented into the Middle East and Africa. The increasing development in healthcare infrastructure and growing economy in countries such as Kuwait, Iran, Israel, and Iraq drive the market growth in this region. 
Key Players
GlaxoSmithKline Plc. (UK), AstraZeneca (UK), Pfizer, Inc. (US), Becton Dickson & Company (US), Dr. Reddy’s Laboratories Ltd. (India), Sanofi-Aventis (UK), Merck & Co. (US), Cadila Pharmaceuticals (India), AEGIS THERAPEUTICS LLC (US), Novartis AG (UK) , Johnson & Johnson Services, Inc (US) and 3M COMPANY (US) are some of the key players in the global nasal drug delivery market.
Regional Market Summary
Geographically, the market has been segmented, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the global nasal drug delivery market owing to an increasing prevalence of rhinitis, congestion, sinusitis, and respiratory allergic reactions.
Additionally, the well-developed healthcare sector and presence of a large number of medical device companies in this region boosts the market growth. According to the Centers for Disease Control and Prevention January 2017, 30.8 million adults were diagnosed with sinusitis in the US.
Europe is expected to hold the second-largest position in the global nasal drug delivery market. The presence of a large patient population suffering from chronic disorders, increasing technological advancement in the healthcare industry, and growing mergers and acquisitions between healthcare companies drives the market growth in this region.
Alabama Nasal Drug Delivery Association (ADMEA) is a Europe based non-profit organization involved in providing home medical equipment. The presence of such organization in Europe enhances the market growth during the forecasted period.
Asia-Pacific is expected to be fastest-growing region owing to the growing geriatric population and increasing incidences of allergy diseases, which is a common cause of respiratory problems in developing countries.
The Middle East & Africa holds the least share of the market. A majority of the market share of this region is expected to be held by the Middle East due to growing government initiatives for the healthcare sector in this region.
Posted by at No comments:
Labels:

Cough Syrup Market Global Sales, Revenue, Price and Gross Margin Forecast To 2023


Global Cough Syrup Market: Information by Product Type (Combination {Dextromethorphan + Guaifenesin, Guaifenesin + Pseudoephedrine and Brompheniramine + Pseudoephedrine} and Individual {Dextromethorphan, Guaifenesin, Ambroxol and Codeine}), by Category (Cough Suppressants and Expectorants), by Application (Adults and Children) and by Region ( Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast till 2026
Market Scenario:
The Global Cough Syrup Market is expected to register a CAGR of 3.45% to reach USD 5,139.63 million by 2026. Cough syrups are the medication used for the temporary relief of coughs, sneezing, or runny noses due to the common cold, hay fever, or other upper respiratory allergies.
The increasing incidence of respiratory disorders along with the rising air pollution are some of the key factors contributing to the growth of the cough syrup market. Additionally, the growing geriatric population, along with an active pharmaceutical sector, are boosting market growth as aged people are more prone to respiratory disorders. Furthermore, the market is expected to witness lucrative growth due to increasing product developments.
However, product recalls, and the stringent regulatory scenario are hampering the growth of the Cough Syrupmarket size.
Market Dynamics
Rising air pollution is acting as a driver for the growth of the market. Air pollution is a major environment-related health threat that stands as a risk factor for both acute and chronic respiratory diseases. According to a report by the Forum of International Respiratory Societies (FIRS), tobacco smoke, indoor air pollution from burning fuels, and air pollution from traffic and industrial sources are highlighted as the primary contributing factors for most respiratory conditions. World Health Organization (WHO) estimated that 4.3 million deaths per year could be attributed to indoor air pollution. Most diseases and deaths that can be attributed to prolonged exposure to poor indoor air quality occurs primarily in women and children, especially in low-income families. Exposure to indoor smoke used for heating and cooking leads to COPD, lung cancer, and, in children, it causes pneumonia and asthma. This large population affected with respiratory disorders due to air pollution is driving the market for cough syrup market as it is a crucial medicine used for the treatment of such diseases.
Segmentation
The global cough syrup market has been segmented into product type, category, and application. Based on product type, the market has been segregated into combination and individuals. Combination product type has been further classified as dextromethorphan + guaifenesin, guaifenesin + pseudoephedrine, and brompheniramine + pseudoephedrine. The individual product type has been further divided into dextromethorphan, guaifenesin, ambroxol, and codeine. Based on the category, the market has been segmented into cough suppressants and expectorants. And by application, the cough syrup market has been categorized as adults and children.
Regional Analysis
The global cough syrup market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to hold a maximum share of the global cough syrup market, and the regional market is projected to register a CAGR of 3.16% during the forecast period. The presence of significant market players in the region, strategic acquisitions by major players to enhance product portfolio, increasing cases of respiratory disorders, and availability of advanced medications for the treatment of chronic obstructive pulmonary disease (COPD) is expected to drive the market growth in this region to combat these concerns effectively through the use of cough syrups.
Europe accounts for the second-largest, in the global cough syrup market, majorly due to the presence of key players such as Novartis, GlaxoSmithKline, and Reckitt Benckiser Group PLC. The cough syrup market in Europe is expected to be driven by the growth of the pharmaceutical industry in Germany, France, and the UK.
Asia-Pacific is estimated to be the fastest-growing market due to the continuous development in developing countries such as India and China. High prevalence of respiratory disorders due to tobacco smoke, exposure to air pollutants at home and the workplace, vehicular pollution, and indoor air pollution from biological agents related to damp and mold further increase the risk of respiratory disease in children and adults in these countries.
The Middle East & Africa cough syrup market has been segmented into major two regions, the Middle East and Africa. The developed countries in the region, such as the UAE and Saudi Arabia, are the ones with the maximum share of the cough syrup market. The advancing healthcare infrastructure, increasing healthcare expenditure, and increasing per capita disposable incomes of the people in these countries are some reasons leading to the large share of the market in these countries. Africa is the least developed region with limited healthcare resources and facilities for the people. The low growth rate due to less developed and less efficient health systems is hampering the growth of the market.
Key Players
The prominent players in the global cough syrup market are Pfizer, Inc. (US), Novartis AG (Switzerland), Merck KGaA (US), Johnson & Johnson Services, Inc. (US), GlaxoSmithKline PLC (UK), Acella Pharmaceuticals, LLC (US), Procter & Gamble (US), Reckitt Benckiser Group PLC (UK), Abbott (US), and Sanofi (France).
The players operating in the global cough syrup market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
  • In February 2019, Merck invested USD 70 million to expand its research & development (R&D) facility in Billerica, Massachusetts for the development of innovative clinical pipeline products.
  • In July 2018, Johnson & Johnson acquired Zarbee's Naturals, a drug-free children's cough syrup. This enabled the company to broaden its product portfolio globally.
  • In December 2016, Pfizer, Inc., launched a series of products as a line extension under the Corex brand name. The first launch was on December 2016, and subsequent launches were conducted in 2017. These formulations were duly approved by central and state regulators.
Bottom of Form
Browse More Healthcare Reports @
https://www.marketresearchfuture.com/categories/healthcare-market-report

Posted by at No comments:
Labels:

Global Veterinary Imaging Market Trends, Demand and Forecast to 2023

Global Veterinary Imaging Market: Information by Product Type (Instruments (Ultrasound Imaging Systems, Radiography (X-Ray) Systems, Computed Tomography Imaging Systems, Magnetic Resonance Imaging Systems), Veterinary Imaging Reagents, Veterinary Software), Animal Type (Small Companion Animals, Large Animals and others), Therapeutic Areas (Orthopedics and Traumatology, Cardiology, Neurology, Oncology and others), End User (Hospitals & Clinics, Academic Institutes and Others) & Region - Forecast till 2025
Market Scenario
The Global Veterinary Imaging Market is expected to register a CAGR of 7.14% to reach USD 2167.78 million by 2025. Veterinary imaging is the noninvasive method that helps to diagnose disease by making medical images of the veterinary body. We have various advanced imaging technology used for veterinary patients. Veterinary imaging instruments are used to diagnosis of chronic disease and getting medical images of animals. Notably, the increasing prevalence of zoonotic diseases, significant rise in pet insurance purchases, and increased number of veterinary practitioners are promoting the growth of the veterinary imaging market globally.
The market growth is mainly driven by increasing incidence of zoonotic diseases, increasing expenditure on pet insurance, and technological advancements in veterinary imaging. However, high procedure cost and lack of skilled veterinarians may slow the growth of the market.
Market Dynamics
Increasing expenditure on the pet is driving the growth of the market. Pet insurance covers various minor to major medical expenses such as accidents, chronic conditions, wellness, and routine care coverage, medication coverage, diagnostic testing and imaging, others. Though pet insurance does not provide 100% coverage, it reimburses around 80% of the total pet medical expenses. According to the North American Pet Health Insurance Association (NAPHIA), North America’s pet health insurance growth was exceeded by 17.2% from 2014 to 2015. It is also reported that the total number of insured pets reached 1.6 million at the end of 2015.
Pet owners spend a lot on routine vet expenses and surgical vet visits. As per the data suggested by The American Pet Products Association (APPA), around 65% of the US population owns a pet, and the US pet industry expenditure in 2015 was USD 60.3 million, which is exceeded to USD 62.8 million. Thus, with the growing spending on animal healthcare, the demand for veterinary diagnosis and the equipment required for the same will also increase, which boosts the growth and veterinary imaging market size.
Segmentation
The global veterinary imaging market is segmented into product type, animal type, therapeutic area, and end user. On the basis of product type, the market is segmented into instruments, veterinary imaging reagents, and veterinary software. On the basis of animal type, it is segmented into small companion animals and large animals. On the basis of the therapeutic area, the veterinary imaging market segmented into orthopedics and traumatology, cardiology, neurology, and oncology. On the basis of end user, the Veterinary Imaging market segmented into hospitals & clinics, and academic institutes.
Regional Analysis
The global veterinary imaging market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas accounted for the largest market share in 2018, and the regional market is projected to register a CAGR of 7.62% during the forecast period. The larger share is majorly attributed to the growth in adoption of pet animals, increasing veterinary healthcare expenditure, increasing demand for pet insurance, and increasing pet ownership. According to the report published by the American Pet Products Association, from 2017 to 2018, 68% of the US households or 85 million families have a pet.
Europe is the second-largest market for veterinary imaging owing to the presence of large market players, innovative advanced technology, increasing companion animal ownership, and the presence of veterinaries.
The Asia Pacific region accounted the third-largest market owing to the presence of large animal population, increasing disposal income, increasing nuclear families preferring to have pets and increased investments by the American and European market giants in Asian countries such as China and India. India held a share of 15.9% in the Asia-Pacific veterinary imaging market in 2018.
The market in the Middle East and Africa is constrained due to poor development of the animal industry and the low productivity of the maximum breeds in the region.
Key Players
The prominent players in the global veterinary imaging market are Esaote SpA (Italy), GE Healthcare (US), Medical Imaging/IMCO, Inc. (US), BCF (Scotland), Fujifilm Holding Corporation (Japan), Heska Corporation (US), Diagnostic Imaging System, Inc. (US), Canon Inc. (Tokyo), Carestream Health (US), and Merry X-Ray (US).
The players operating in the global veterinary imaging market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
  • In March 2019, Esaote SpA launched the new ultrasound platform MyLabX8 for increasing efficiency of ultrasound machines and to maintain the workflow.
  • In October 2018, GE Healthcare announced a strategic collaboration with SonoSim to encourage education and training about ultrasound devices. This collaboration is likely to help the company to increase its customer base.
  • In June 2018, Fujifilm Holding Corporation acquired Irvine Scientific Sales Company, Inc. for USD 800 million. With this acquisition, Fujifilm is likely to enter into the cell culture media business.
Posted by at No comments:
Subscribe to: Posts (Atom)